What does Altimmune, Inc. do?
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated…
What is Altimmune, Inc.'s P/E and P/B ratio?
Altimmune, Inc. has a P/E ratio of -2.8 and a P/B ratio of 0.87.
What is Altimmune, Inc.'s debt-to-equity ratio?
Altimmune, Inc. has a debt-to-equity ratio of 0.08.
How much does Altimmune, Inc. owe compared with what it owns?
Altimmune, Inc. owes $0.10 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Altimmune, Inc.'s Positivity rank?
Altimmune, Inc. is ranked #2,186 of 6,775 companies globally and #603 of 4,000 in United States on PositoAI, with a Positivity Score of 21,858.
Does Altimmune, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Altimmune, Inc..
Where can I read the latest news about Altimmune, Inc.?
Recent headlines about Altimmune, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Altimmune, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Altimmune, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.